Abeona Therapeutics Inc. (ABEO) stock
Close on Nov 11, 2026Market cap $131.52MP/E –Yield –
Abeona Therapeutics Inc. reported revenue of $39.01M for the twelve months to Sep 30, 2026. Free cash flow was -$66.35M. At the latest close the market valued the company at $131.52M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $131.52M
- P/E ratio
- –
- Price to sales
- 3.37
- Price to book
- 1.04
- Dividend yield
- –
- Free cash flow yield
- -50.44%
Fundamentals
- Revenue
- $39.01M
- Net income
- -$62.53M
- EPS, diluted
- -$1.05
- Free cash flow
- -$66.35M
- Book value per share
- $2.18
- Diluted shares
- 58M
Trading
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Previous close
- $2.46
- Open
- $2.45
- Day's range
- $2.24 – $2.50
- Volume
- 6,418,548
- Average volume (20 days)
- 1,967,226
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.31
- 52-week range
- $2.24 – $7.65
- RSI (14 days)
- 17.6
- Volatility (1 year)
- 67.0%
- Relative volume
- 4.32×
- WACC
- 11.5%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABEO | S&P 500 | Difference | ABEO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -53.4% | -2.4% | −51.0 pts | ||
| 3 months | -68.9% | -1.2% | −67.8 pts | ||
| Year to date | -56.4% | +12.3% | −68.6 pts | ||
| 1 year | -44.8% | +12.4% | −57.3 pts | ||
| 3 years | -43.8% | +78.8% | −122.6 pts | -17.5% | +21.4% |
| 5 years | -90.2% | +75.2% | −165.4 pts | -37.2% | +11.9% |
| 10 years | -98.6% | +311.1% | −409.7 pts | -34.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Abeona Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
About Abeona Therapeutics
Pharmaceutical Preparations
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell and gene therapies for life-threatening genetic diseases. The company's primary commercial product is ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene-modified cellular sheet therapy developed to treat wounds in adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa. In addition to its lead therapy, the company develops adeno-associated virus-based gene therapies targeting ophthalmic conditions through its proprietary and licensed AIM capsid technology platform. Abeona serves patients with severe genetic conditions through partnerships with academic researchers, patient advocacy organizations, caregivers, and biotechnology firms.
Company profile, executives and historyAbeona Therapeutics stock: common questions
What is Abeona Therapeutics's stock price?
ABEO closed at $2.30 on Nov 11, 2026, down 6.31% on the day. Over the past 52 weeks it traded between $2.24 and $7.65.
What is Abeona Therapeutics's market cap?
Abeona Therapeutics was worth $131.52M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABEO's P/E ratio?
Abeona Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.05), so it has no meaningful P/E ratio.
How much revenue does Abeona Therapeutics make?
Abeona Therapeutics reported revenue of $39.01M for the twelve months to Sep 30, 2026.
Does Abeona Therapeutics pay a dividend?
No. Abeona Therapeutics has not paid a cash dividend over the last twelve months.
When does Abeona Therapeutics report earnings next?
Abeona Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ABEO stock performed over the past year?
Including dividends, ABEO returned -44.8% over the past year, against +12.4% for the S&P 500.
How many ABEO shares are sold short?
17M shares were sold short at the latest FINRA report, 33.65% of the float, or 21.7 days of average trading volume.
Who are Abeona Therapeutics's competitors?
Companies most similar to Abeona Therapeutics by business, industry and size include KROS, LXRX, AQST, STOK, VRDN.
See a number that looks wrong?